EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

EEDGAR/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Groups
  • Trending
  • News

More

  • Pricing
  • Community
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice. EDGAR is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. EDGAR/calls is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Pulling SEC filings + quote and writing the call…

EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity
← New search
Home›Stocks›NKTX

NKTX

Nkarta, Inc.

Next earnings Aug 10, 2026 · consensus $-0.39 EPS

Last earnings +3.1% on 2026-05-12

Hold
$2.83
▲ +1.80%
$2.83▲ +62.18%
over 1Y
L $1.66EODHDH $3.49
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+1.8%
1W+1.4%
1M-11.3%
3M+37.4%
YTD+51.3%
1Y+62.2%
OverviewFinancialsValuationQualityTimelineFilings
Rating
Hold
Quality
D
Valuation
Fair value
Filings
Watch
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 10 analysts
Strong Buy

Conservative balance sheet (liabilities/equity 0.29x).

Revenue (FY2025) $0.00 · FY2025

Nkarta, Inc. shows $0.00 in FY2025 revenue, and -33.3% ROE.

Financials · annual, by fiscal year

Line itemFY21FY22FY23FY24FY25
Revenue———$0.00$0.00
Gross profit—————
Operating income-$86.4M-$119M-$132M-$128M-$122M
Net income-$86.1M-$114M-$118M-$109M-$104M
Diluted EPS-$2.62-$2.61-$2.40-$1.60-$1.41
Net margin—————

Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.

Key statistics

Valuation

Enterprise value$162M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-51.6%
FCF yield-44.6%

Quality & risk

ROIC (est.)-30.9%
Free cash flow-$89.9M
Total debt—
Net cash$39.6M
Altman Z-Score-1.15 distress
Piotroski F-Score1/7

Capital returns

Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+0.5%

Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.

Disclosure timeline

SEC · 8-Ks + reports
Some governance/structural items recently, but no outright red flags.
  1. 8-K Shareholder vote2026-06-11
  2. 8-K Earnings results2026-05-12
  3. 10-Q Quarterly report2026-05-12
  4. DEF 14A Proxy statement2026-04-23
  5. 8-K Other event2026-03-26
  6. 8-K Earnings results2026-03-25
  7. S-3 Shelf registration (potential raise)2026-03-25
  8. 10-K Annual report2026-03-25
  9. 8-K Earnings results2025-11-10

Recent filings

all on EDGAR ↗
4Period ending 2026-06-182026-06-22open ↗8-KPeriod ending 2026-06-102026-06-11open ↗4Period ending 2026-06-102026-06-11open ↗4Period ending 2026-06-102026-06-11open ↗4Period ending 2026-06-102026-06-11open ↗4Period ending 2026-06-102026-06-11open ↗4Period ending 2026-06-102026-06-11open ↗4Period ending 2026-06-102026-06-11open ↗4Period ending 2026-06-102026-06-11open ↗4Period ending 2026-06-102026-06-11open ↗SCHEDULE 13D/AFiling2026-05-19open ↗10-QPeriod ending 2026-03-312026-05-12open ↗

Quality score

D
ValueGrowthProfitHealthMom.
Value—
GrowthC+
ProfitabilityF
Financial healthB-
Momentum—
  • ✗Profitable (positive net income)
  • ✗Return on equity above 15%
  • ✓Liabilities below 2× equity
Revenue
$0.00
Net margin
—
ROE
-33.3%
P/E
—

SEC fundamentals · FY 2025

■ revenue · ■ net income, by fiscal year

Revenue$0.00
Net income-$104M+4.3%
Operating income-$122M+4.8%
Diluted EPS-$1.41+11.9%
Cash & equivalents$39.6M+42.2%
Total assets$404M-19.4%
Total liabilities$91.9M-1.4%
Stockholders' equity$312M-23.4%
L/E: 0.29x

Frequently asked

Is Nkarta, Inc. (NKTX) a buy?
NKTX currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.29x).
What is Nkarta, Inc.'s quality score?
NKTX scores 49.102564102564095/100 (grade D) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.

Sources: SEC EDGAR (CIK 0001787400, latest 10-Q filed 2026-05-12) · EODHD · as of 6/23/2026, 1:56:20 AM.

Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.

Insider activity

Form 4 · SEC

Last 90 days: 0 open-market buys · 1 sale

2026-06-18
HASTINGS PAUL J
Chief Executive Officer
Sell1.78K @ $2.71$4.81K

Earnings history

beat/miss · move
2026-05-12Beat +2.6% est▲ +3.14%8-K ↗
2026-03-25Miss -14.1% est▲ +3.90%8-K ↗
2025-11-10Beat +9.3% est▲ 0.00%8-K ↗
2025-08-12Beat +14.4% est▼ -2.49%8-K ↗
2025-05-14—▼ -3.61%8-K ↗
2025-03-26—▼ -4.20%8-K ↗

Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.

Recent news

market news →
Nkarta to Participate in H.C. Wainwright 4th Annual Cell Therapy Virtual ConferenceBullish
globenewswire.com· 2026-06-26
Nkarta GAAP EPS of -$0.37 in-lineBullish
seekingalpha.com· 2026-05-12
NKTX Stock Up on Upbeat Regulatory Update on Lead Autoimmune ProgramBullish
finance.yahoo.com· 2026-04-17
Nkarta files $350M shelf offering, plans $100M ATM stock sale via StifelBullish
seekingalpha.com· 2026-03-26
CD19 Inhibitors Market to Witness Significant Expansion During the Forecast Period (2025-2034) as Autoimmune and Oncology Pipelines Accelerate | DelveInsightBullish
finance.yahoo.com· 2026-03-10
Nkarta to Participate in March Investor ConferencesBullish
globenewswire.com· 2026-02-27

Vs tracked universe

compare →

1043 tracked peers · median

EDGAR Score49 vs 67
Revenue growth— vs 7.1%
Net margin— vs 10.5%
Return on equity-33.3% vs 12.3%
P/E— vs 25.5

News sentiment

EODHD · 2d
Bearish
-0.21
vs typical · 2 articles
↑ improving

Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.